Document Type : Research Article
Abstract
Introduction: Postmenopausal osteoporosis is a major health problem in Indian women as it increases chances of both vertebral and non-vertebral fractures. The benefits of the standard treatment regimen for prevention of postmenopausal osteoporosis are not encouraging. Denosumab, in various international studies is found as an effective treatment modality for prevention of postmenopausal osteoporosis. However, there is scarcity of data of Indian postmenopausal women. Therefore, present study is an attempt to observe the treatment effect of denosumab for prevention of postmenopausal osteoporosis. Objective: To observe the treatment effect of denosumab in patients suffering from postmenopausal osteoporosis in terms of bone mineral density(BMD).
Methods: This randomized control study was done in 62 randomly selected patients with postmenopausal osteoporosis at SMS Hospital, Jaipur. After administering denosumab (60 mg every 6 months), we measured lumbar spine, total hip and distal radius BMD at 6 and 12 months.
Results: At 6 months, lumbar spine BMD increased more in denosumab group(0.29±0.17, P˂0.001) compared to control group(0±0.29, P˂0.001) and at the end of 12 months also, lumbar spine BMD increased more in denosumab group(0.56±0.24, P˂0.001) compared to control group(-0.03±0.41, P˂0.001). Similarly, at 6 months, total hip BMD increased more in denosumab group(0.38±0.23, P˂0.001) compared to control group(-0.08±0.22, P˂0.001) and at the end of 12 months, total hip BMD increased more in denosumab group(0.82±0.3, P˂0.001) compared to control group(-0.1±0.36, P˂0001). At 6 months, distal radius BMD increased more in denosumab group(0.27±0.25) compared to control group(0.00±0.37) and at 12 months, distal radius BMD increased more in denosumab group(0.58±0.34) compared to control group(-0.04±0.43).
Conclusions: Denosumab is effective to treat postmenopausal osteoporosis and it is more effective at hip than at lumbar spine and radius. To conclude further treatment is needed as sequential therapy because on stopping the treatment BMD again start receding over the period.